Cargando…

Gene Set-Based Functionome Analysis of Pathogenesis in Epithelial Ovarian Serous Carcinoma and the Molecular Features in Different FIGO Stages

Serous carcinoma (SC) is the most common subtype of epithelial ovarian carcinoma and is divided into four stages by the Federation of Gynecologists and Obstetrics (FIGO) staging system. Currently, the molecular functions and biological processes of SC at different FIGO stages have not been quantifie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Chia-Ming, Chuang, Chi-Mu, Wang, Mong-Lien, Yang, Ming-Jie, Chang, Cheng-Chang, Yen, Ming-Shyen, Chiou, Shih-Hwa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926420/ https://www.ncbi.nlm.nih.gov/pubmed/27275818 http://dx.doi.org/10.3390/ijms17060886

Ejemplares similares

Gene Set−Based Integrative Analysis Revealing Two Distinct Functional Regulation Patterns in Four Common Subtypes of Epithelial Ovarian Cancer
por: Chang, Chia-Ming, et al.
Publicado: (2016)

Integrating the dysregulated inflammasome-based molecular functionome in the malignant transformation of endometriosis-associated ovarian carcinoma
por: Chang, Chia-Ming, et al.
Publicado: (2017)

Dysregulated Immunological Functionome and Dysfunctional Metabolic Pathway Recognized for the Pathogenesis of Borderline Ovarian Tumors by Integrative Polygenic Analytics
por: Chang, Chia-Ming, et al.
Publicado: (2021)

Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis
por: Chang, Cheng-Chang, et al.
Publicado: (2018)

Evaluation method for the potential functionome harbored in the genome and metagenome
por: Takami, Hideto, et al.
Publicado: (2012)

Comparative Analysis of Proteomes and Functionomes Provides Insights into Origins of Cellular Diversification
por: Nasir, Arshan, et al.
Publicado: (2013)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

An automated system for evaluation of the potential functionome: MAPLE version 2.1.0
por: Takami, Hideto, et al.
Publicado: (2016)

Survival analysis of revised 2013 FIGO staging classification of epithelial ovarian cancer and comparison with previous FIGO staging classification
por: Paik, E Sun, et al.
Publicado: (2015)

A Suggested Modification to FIGO Stage IV Epithelial Ovarian Cancer
por: Métairie, Marie, et al.
Publicado: (2023)

Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma
por: Sung, Pi-Lin, et al.
Publicado: (2015)

Does adding intraperitoneal paclitaxel to standard intraperitoneal regimen yield incremental survival? A propensity score-matched cohort study
por: Chang, Yen-Hou, et al.
Publicado: (2016)

An increased risk of epithelial ovarian cancer in Taiwanese women with a new surgico-pathological diagnosis of endometriosis
por: Wang, Kuan-Chin, et al.
Publicado: (2014)

Synergistic AHR Binding Pathway with EMT Effects on Serous Ovarian Tumors Recognized by Multidisciplinary Integrated Analysis
por: Su, Kuo-Min, et al.
Publicado: (2021)

Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: implications for adjuvant radiotherapy
por: Chang, Jee Suk, et al.
Publicado: (2013)

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
por: Ducie, Jennifer, et al.
Publicado: (2017)

Development and Validation of Prognostic Nomogram for Primary Peritoneal Serous Carcinoma Compared With FIGO Staging System: A Population-Based Study
por: Chen, Ming, et al.
Publicado: (2021)

Parametrial involvement and decreased survival of women with FIGO stage IIIC1 cervical cancer
por: Chang, Hong, et al.
Publicado: (2023)

Adjuvant brachytherapy for FIGO stage I serous or clear cell endometrial cancer
por: Jeans, Elizabeth B, et al.
Publicado: (2021)

Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers
por: Sartorius, Céline Montavon, et al.
Publicado: (2018)

FIGO staging in ovarian carcinoma and histological subtypes
por: Kehoe, Sean
Publicado: (2020)

Recurrent ovarian mixed germ cell tumor with unusual malignant transformation: a case report
por: Lee, Yi-Le, et al.
Publicado: (2019)

The Risk of Epithelial Ovarian Cancer of Women With Endometriosis May be Varied Greatly if Diagnostic Criteria Are Different: A Nationwide Population-Based Cohort Study
por: Lee, Wen-Ling, et al.
Publicado: (2015)

Poly(ADP-Ribose) Polymerase 1: Cellular Pluripotency, Reprogramming, and Tumorogenesis
por: Jiang, Bo-Hua, et al.
Publicado: (2015)

Oncostatin M suppresses metastasis of lung adenocarcinoma by inhibiting SLUG expression through coordination of STATs and PIASs signalings
por: Pan, Chih-Ming, et al.
Publicado: (2016)

Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage
por: Muller, Petr, et al.
Publicado: (2019)

The Potential Role of Complement System in the Progression of Ovarian Clear Cell Carcinoma Inferred from the Gene Ontology-Based Immunofunctionome Analysis
por: Su, Kuo-Min, et al.
Publicado: (2020)

Pathogenesis and New Therapeutic Targets of Ovarian Cancer
por: Shih, Ie-Ming, et al.
Publicado: (2012)

Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma
por: Ho, Chih-Ming, et al.
Publicado: (2012)

Ovarian cancer: imaging in treatment selection and planning with FIGO update
por: Sala, Evis
Publicado: (2014)

Ovarian cancer: imaging in treatment selection and planning with FIGO update
por: Sala, Evis
Publicado: (2015)

Targeting cancer stem cells: emerging role of Nanog transcription factor
por: Wang, Mong-Lien, et al.
Publicado: (2013)

Prerequisites to improve surgical cytoreduction in FIGO stage III/IV epithelial ovarian cancer and subsequent clinical ramifications
por: de Jong, Diederick, et al.
Publicado: (2023)

Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis
por: Chang, Yen-Hou, et al.
Publicado: (2016)

Genomic variance of Open Reading Frames (ORFs) and Spike protein in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
por: Tsai, Ping-Hsing, et al.
Publicado: (2020)

BRAF(V600E)-mutated ovarian serous borderline tumors are at relatively low risk for progression to serous carcinoma
por: Chui, M. Herman, et al.
Publicado: (2019)

Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics
por: Gross, Amy L., et al.
Publicado: (2010)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

MDCT-Based Radiomics Features for the Differentiation of Serous Borderline Ovarian Tumors and Serous Malignant Ovarian Tumors
por: Yu, Xin-ping, et al.
Publicado: (2021)

Hormone Receptors in Serous Ovarian Carcinoma: Prognosis, Pathogenesis, and Treatment Considerations
por: Voutsadakis, Ioannis A.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p9rgb1h9um6co5qp7b5k55qehl